Literature DB >> 10686294

Species selectivity of a small molecule antagonist for the CCR1 chemokine receptor.

M Liang1, M Rosser, H P Ng, K May, J G Bauman, I Islam, A Ghannam, P J Kretschmer, H Pu, L Dunning, R M Snider, M M Morrissey, J Hesselgesser, H D Perez, R Horuk.   

Abstract

The species specificity of a small molecule antagonist for the human CCR1 chemokine receptor, 2-2-diphenyl-5-(4-chlorophenyl)piperidin-1-yl)valeronitrile (CCR1 antagonist 1), has been examined using cloned CCR1 receptors from various species. The compound was able to bind to rabbit, marmoset, and human CCR1, and was able to block the functional activation of these receptors. However, it failed to significantly displace radiolabeled macrophage inflammatory protein-1alpha (MIP-1alpha) binding to mouse CCR1 at concentrations up to 10 microM. These data suggested that the antagonist binding site is well-conserved in rabbit, marmoset and human CCR1, but not in mouse CCR1. The functional selectivity and mechanism of action for CCR1 antagonist 1 were further characterized. CCR1 antagonist 1 blocked the increase in intracellular Ca(2+) stimulated by CCR1 agonists, but had no effect on N-formyl-Met-Leu-Phe (FMLP), monocyte chemotactic protein-1 (MCP-1) and stromal-derived factor 1alpha (SDF1alpha)-induced Ca(2+) mobilization, demonstrating functional selectivity for CCR1. Since CCR1 antagonist 1 is a functional antagonist of marmoset and rabbit CCR1 receptors, it should be possible to test its efficacy in animal models of disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10686294     DOI: 10.1016/s0014-2999(99)00863-8

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

1.  A chemokine receptor CCR-1 antagonist reduces renal fibrosis after unilateral ureter ligation.

Authors:  Hans-Joachim Anders; Volker Vielhauer; Michael Frink; Yvonne Linde; Clemens D Cohen; Simone M Blattner; Matthias Kretzler; Frank Strutz; Matthias Mack; Hermann-Josef Gröne; James Onuffer; Richard Horuk; Peter J Nelson; Detlef Schlöndorff
Journal:  J Clin Invest       Date:  2002-01       Impact factor: 14.808

2.  Therapeutic targeting of CCR1 attenuates established chronic fungal asthma in mice.

Authors:  Kristin J Carpenter; Jillian L Ewing; Jane M Schuh; Traci L Ness; Steven L Kunkel; Monica Aparici; Montserrat Miralpeix; Cory M Hogaboam
Journal:  Br J Pharmacol       Date:  2005-08       Impact factor: 8.739

Review 3.  Using guinea pigs in studies relevant to asthma and COPD.

Authors:  Brendan J Canning; Yangling Chou
Journal:  Pulm Pharmacol Ther       Date:  2008-02-02       Impact factor: 3.410

4.  Pharmacological blockade of CCR1 ameliorates murine arthritis and alters cytokine networks in vivo.

Authors:  M Amat; C F Benjamim; L M Williams; N Prats; E Terricabras; J Beleta; S L Kunkel; N Godessart
Journal:  Br J Pharmacol       Date:  2006-10-03       Impact factor: 8.739

5.  A QSAR study of some cyclobutenediones as CCR1 antagonists by artificial neural networks based on principal component analysis.

Authors:  M Shahlaei; A Fassihi; L Saghaie; E Arkan; A Pourhossein
Journal:  Daru       Date:  2011       Impact factor: 3.117

Review 6.  Chemokine receptors: multifaceted therapeutic targets.

Authors:  Amanda E I Proudfoot
Journal:  Nat Rev Immunol       Date:  2002-02       Impact factor: 53.106

Review 7.  Chemokines in allergic airway disease.

Authors:  Clare M Lloyd; Sara M Rankin
Journal:  Curr Opin Pharmacol       Date:  2003-08       Impact factor: 5.547

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.